Oncology Pharma Inc. (ONPH)
OTC PINK OTC PINK Primary Summary
Oncology Pharma Inc. (ONPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oncology Pharma Inc. ever had a stock split?
Oncology Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | George Malesek CEO | OTC PINK Exchange | 68235J201 CUSIP |
| US Country | 1 Employees | - Last Dividend | 4 Jan 2016 Last Split | - IPO Date |
Overview
Oncology Pharma Inc. is a healthcare company specializing in oncology, focusing on the development, manufacture, and commercialization of therapeutic solutions. This company stands at the forefront of research and development in the fight against cancer, leveraging innovative strategies and partnerships to advance its mission. Oncology Pharma Inc. embarked on a significant evolution by renaming itself from SourcingLink.net Inc. to its current name in June 2019, marking a strategic pivot towards oncology. Founded in 1993 and nestled in the bustling biotech hub of San Francisco, California, this corporation has firmly established itself within the competitive landscape of medical research and pharmaceuticals. A key aspect of its strategy involves a partnership with Kalos Therapeutics Inc., aiming to explore potential treatments for the COVID-19 virus, which demonstrates its adaptability and commitment to addressing immediate global health crises alongside its oncology focus.
Products and Services
- Therapeutic Development and Commercialization: Oncology Pharma Inc. dedicates itself to the lifecycle of oncology therapeutics, from initial development through to commercialization. The focus on creating effective treatments involves rigorous research, clinical trials, and a commitment to safety and efficacy for cancer patients. The involvement spans multiple types of cancer, aiming to provide targeted and comprehensive solutions for individuals battling this complex disease.
- Collaboration and Licensing: A noteworthy collaboration exists between Oncology Pharma Inc. and Kalos Therapeutics Inc., particularly in the face of the ongoing COVID-19 pandemic. This partnership illustrates the company's versatility and its ability to extend its research efforts to infectious diseases, seeking to uncover and develop potential therapeutic options for the COVID-19 virus. This strategic alliance leverages the strengths of both entities to expand the scope of research and potential treatment pathways.
